
ARDT Stock Forecast & Price Target
ARDT Analyst Ratings
Bulls say
Ardent Health Inc. demonstrated a strong financial performance with an EBITDA of $143 million, representing a 46% year-over-year increase, alongside an improved margin of 9.1%, up by 240 basis points compared to the previous year. The company experienced a notable growth in inpatient admissions, which rose 5.8% year-over-year, significantly outpacing the peer average of 1.7%, indicating robust demand in its service offerings. Additionally, improvements in contract labor costs and strategic investments in capital expenditures suggest a focused approach towards efficiency and growth in the healthcare market.
Bears say
The negative outlook on Ardent Health Inc. is primarily driven by a significant EBITDA miss of $143 million, reflecting a 2% shortfall against estimates, and underlying performance deterioration exacerbated by one-time gains in the previous quarter. Additionally, a substantial revenue adjustment of $43 million due to the transition to the Kodiak revenue cycle management platform has led to a more conservative stance regarding accounts receivable collectability, suggesting minimal to negative EBITDA growth for 2026. The downward revisions of EBITDA estimates for 2025 and 2026, alongside increasing claims denials and professional fee challenges, indicate persistent financial headwinds that could severely impact cash flow generation moving forward.
This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.
ARDT Analyst Forecast & Price Prediction
Start investing in ARDT
Order type
Buy in
Order amount
Est. shares
0 shares